Company Conference Call October 1, 2024 9:00 AM ETCompany ParticipantsKarim Beguir - Chief Executive Officer, InstaDeepUğur ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who ...

Google DeepMind and BioNTech are building AI lab assistants to help researchers plan scientific experiments and better predict their outcomes as companies race to find specialised applications for ...

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we ...

Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipeline Highlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of ...

Biotech company Regeneron Pharmaceuticals lost a bid on Friday to be held immune from allegations that it misused a patented ...

On Wednesday, TD Cowen maintained its Hold rating on BioNTech (NASDAQ:BNTX), with a consistent price target of $85.00. The firm's stance comes after a detailed review of the company's advancements ...

Google DeepMind by Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) and BioNTech (NASDAQ:BNTX) are collaborating to develop AI lab ...